AU2001293553A1 - Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment - Google Patents

Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment

Info

Publication number
AU2001293553A1
AU2001293553A1 AU2001293553A AU9355301A AU2001293553A1 AU 2001293553 A1 AU2001293553 A1 AU 2001293553A1 AU 2001293553 A AU2001293553 A AU 2001293553A AU 9355301 A AU9355301 A AU 9355301A AU 2001293553 A1 AU2001293553 A1 AU 2001293553A1
Authority
AU
Australia
Prior art keywords
phosphatidylserine
mimicking
apoptosis
bodies
carrying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001293553A
Other languages
English (en)
Inventor
Anthony E. Bolton
Arkady Mandel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasogen Ireland Ltd
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of AU2001293553A1 publication Critical patent/AU2001293553A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001293553A 2000-09-18 2001-09-18 Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment Abandoned AU2001293553A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2319928 2000-09-18
CA002319928A CA2319928A1 (fr) 2000-09-18 2000-09-18 Entites synthetiques imitant l'apoptose et utilisation de celles-ci pour des traitements medicaux
PCT/CA2001/001328 WO2002024162A1 (fr) 2000-09-18 2001-09-18 Corps synthetiques reproduisant l'apoptose et transportant de la phosphatidylserine, et leur utilisation dans un traitement medical

Publications (1)

Publication Number Publication Date
AU2001293553A1 true AU2001293553A1 (en) 2002-04-02

Family

ID=4167153

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001293553A Abandoned AU2001293553A1 (en) 2000-09-18 2001-09-18 Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment

Country Status (6)

Country Link
US (1) US6953591B2 (fr)
EP (1) EP1324750A1 (fr)
JP (1) JP2004508423A (fr)
AU (1) AU2001293553A1 (fr)
CA (2) CA2319928A1 (fr)
WO (1) WO2002024162A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI281407B (en) * 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
CA2458720A1 (fr) * 2001-09-18 2003-03-27 Vasogen Ireland Limited Entites synthetiques simulant l'apoptose et leur utilisation en therapie
US20050058767A1 (en) * 2001-09-18 2005-03-17 Bolton Anthony E Process for accelerating recovery from trauma by using apoptosis-mimicking synthetic or natural entities
GB0207653D0 (en) * 2002-04-03 2002-05-15 Lamellar Therapeutics Ltd Methods of using lamellar bodies for therapeutic purposes
WO2005007240A1 (fr) * 2003-07-21 2005-01-27 Vasogen Ireland Limited Traitement combine comprenant des phospholipides pour les troubles neurologiques
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
JP4891522B2 (ja) * 2003-10-03 2012-03-07 株式会社ファンケル 血清ｇｏｔ、ｇｐｔ改善剤
US8022051B2 (en) * 2004-10-20 2011-09-20 Doosan Corporation Composition for protection and improvement of skin, or reinforcing skin barrier function comprising phosphatidylserine
GB0426481D0 (en) 2004-12-02 2005-01-05 Vaccine Technology Ltd Composition
WO2006107107A1 (fr) * 2005-04-01 2006-10-12 Fumitaka Ohsuzu Agent de protection myocardique comprenant un liposome phospholipidique et procédé de prévention d’un trouble du myocarde lors d’une ischémie/reperfusion
US7776818B2 (en) * 2005-09-29 2010-08-17 S-Cell Biosciences, Inc. Methods to treat T-cell disorders using TISF
ITRM20070394A1 (it) * 2007-07-16 2009-01-17 Uni Cattolica Del Sacro Cuo Re Liposomi asimmetrici e loro usi in campo medico.
CN102046151A (zh) * 2008-03-26 2011-05-04 牛津大学 靶向内质网的脂质体
KR20120059447A (ko) 2009-03-27 2012-06-08 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 콜레스테롤 수준 저하 리포좀
WO2011098407A1 (fr) * 2010-02-12 2011-08-18 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Microsphères
AU2011316777A1 (en) * 2010-10-22 2013-06-13 University Of Florida Research Foundation, Inc. Antigen-specific, tolerance-inducing microparticles and uses thereof
CA2834619A1 (fr) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Administration regulee d'immunosuppresseurs a partir de nanovecteurs synthetiques
CN103702687A (zh) 2011-07-29 2014-04-02 西莱克塔生物科技公司 产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
US20150164800A1 (en) * 2012-07-25 2015-06-18 Xetrios Therapeutics, Inc. Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine
JP6580558B2 (ja) 2013-05-03 2019-09-25 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． Ｃｄ４＋制御性ｔ細胞を増強するための方法および組成物
HUE052233T2 (hu) 2013-06-04 2021-04-28 Selecta Biosciences Inc Nem immunszuppresszív, antigénre specifikus immunterápiás ágensek ismételt beadása
WO2015107140A1 (fr) * 2014-01-17 2015-07-23 Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol Immunothérapie reposant sur un liposome
EP3160453A1 (fr) 2014-06-25 2017-05-03 Selecta Biosciences, Inc. Méthodes et compositions de traitement par nanovecteurs de synthèse et inhibiteurs de point de contrôle immunitaire
US10046064B2 (en) 2014-09-07 2018-08-14 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
GB201511058D0 (en) * 2015-06-23 2015-08-05 Lamellar Biomedical Ltd Compositions and methods for using lamellar bodies for therapeutic purposes
WO2017096262A1 (fr) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions et procédés pour atténuer ou prévenir une réponse immunitaire à une molécule thérapeutique immunogène chez des primates non humains
ES2913073T3 (es) 2016-04-29 2022-05-31 Icahn School Med Mount Sinai Direccionamiento del sistema inmunitario innato para inducir tolerancia a largo plazo y resolver la acumulación de macrófagos en aterosclerosis
CN109922819A (zh) 2016-09-27 2019-06-21 西莱克塔生物科技公司 用于治疗癌症的重组免疫毒素
KR20240015743A (ko) 2017-01-07 2024-02-05 셀렉타 바이오사이언시즈, 인크. 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
EP3592389A1 (fr) 2017-03-11 2020-01-15 Selecta Biosciences, Inc. Procédés et compositions associés à un traitement combiné avec anti-inflammatoires et nanovecteurs synthétiques comprenant un immunosuppresseur
BR112020007157A2 (pt) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
KR20210034015A (ko) 2018-07-16 2021-03-29 셀렉타 바이오사이언시즈, 인크. Mma 구축물 및 벡터의 방법 및 조성물
US20200038462A1 (en) 2018-07-16 2020-02-06 Selecta Biosciences, Inc. Methods and compositions of otc constructs and vectors
CN114126666A (zh) 2019-04-28 2022-03-01 西莱克塔生物科技公司 用于治疗针对病毒转移载体具有预先存在的免疫力的对象的方法
JP2022534741A (ja) 2019-05-28 2022-08-03 セレクタ バイオサイエンシーズ インコーポレーテッド 減弱化された抗ウイルス導入ベクター免疫応答のための方法および組成物
WO2022098901A1 (fr) 2020-11-04 2022-05-12 Selecta Biosciences, Inc. Compositions pour réduire des réponses immunitaires contre des immunoglobuline protéases
JP2024502115A (ja) 2021-01-05 2024-01-17 セレクタ バイオサイエンシーズ インコーポレーテッド ウイルスベクター投薬プロトコル
MX2023011004A (es) 2021-03-19 2024-01-08 Trained Therapeutix Discovery Inc Compuestos para regular la inmunidad entrenada y métodos para usarlos.
EP4319747A1 (fr) 2021-04-09 2024-02-14 Selecta Biosciences, Inc. Nanovecteurs synthétiques comprenant un immunosuppresseur en combinaison avec des agonistes du récepteur à l'il-2 à haute affinité destinés à améliorer la tolérance immunitaire
WO2023064350A1 (fr) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Protocoles de dosage de vecteurs viraux
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023086615A1 (fr) 2021-11-14 2023-05-19 Selecta Biosciences, Inc. Dosage multiple avec vecteurs viraux
WO2023133319A1 (fr) 2022-01-10 2023-07-13 Selecta Biosciences, Inc. Agonistes du récepteur de l'il-2 à haute affinité et réduction de dose de nanotransporteur synthétique
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
US20230322884A1 (en) 2022-03-09 2023-10-12 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
WO2023183568A1 (fr) 2022-03-25 2023-09-28 Selecta Biosciences, Inc. Nanovecteurs synthétiques comprenant un immunosuppresseur en association avec des agonistes du récepteur il -2 à haute affinité et des agents anti-igm
WO2023196566A1 (fr) 2022-04-08 2023-10-12 Selecta Biosciences, Inc. Agonistes du récepteur de l'il-2 à haute affinité et immunosuppresseurs pour améliorer la tolérance immunitaire
US20240148841A1 (en) 2022-08-11 2024-05-09 Selecta Biosciences Inc. Compositions and methods related to immunoglobulin proteases and fusions thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1212900B (it) * 1983-11-17 1989-11-30 Valle Francesco Della Uso terapeutico della fosfatidilserina in malattie del sistema nervoso centrale senza effetti sulla coagulazione sanguigna
IL84252A (en) * 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
US5231090A (en) * 1990-07-30 1993-07-27 University Of Miami Treatment for hypercholesterolemia
IT1247165B (it) 1991-03-15 1994-12-12 Fidia Spa Uso terapeutico della fosfatidilserina e derivati in patologie degenerative anche associate a disfunsioni immunitarie.
DE4117629A1 (de) 1991-05-29 1992-12-03 Max Planck Gesellschaft Phospatidylserine
US5292513A (en) * 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
JP3714683B2 (ja) 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US6312719B1 (en) 1994-03-04 2001-11-06 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
WO1995023592A1 (fr) 1994-03-04 1995-09-08 The University Of British Columbia Compositions a base de liposomes et procedes de traitement de l'atherosclerose
US5948756A (en) 1995-08-31 1999-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Therapeutic lipoprotein compositions
US6290987B1 (en) * 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
AU2580801A (en) * 1999-12-14 2001-06-25 Sky High, Llc Phospholipid compositions as anti-inflammation agents
KR20030001375A (ko) 2000-03-07 2003-01-06 이.에프.피. 플로어 프러덕츠 푸스뵈덴 게엠베하 패널의 기계적 연결부
EP1263982A4 (fr) * 2000-03-08 2005-03-09 Nat Jewish Med & Res Center Recepteurs de phosphatidylserine et utilisation de ces recepteurs

Also Published As

Publication number Publication date
CA2422686A1 (fr) 2002-03-28
JP2004508423A (ja) 2004-03-18
US6953591B2 (en) 2005-10-11
WO2002024162A1 (fr) 2002-03-28
EP1324750A1 (fr) 2003-07-09
CA2319928A1 (fr) 2002-03-18
US20020086049A1 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
AU775126C (en) Substituted oxazolidinones and their use in the field of blood coagulation
HUP0203367A3 (en) Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes
AU2001256184A1 (en) 6-aminoalkyl-dihydropyrimidines and the use thereof as medicaments against viraldiseases
AU2001275177A1 (en) Cardiac disease treatment and device
AU2001253565A1 (en) Cardiac disease treatment and device
AU2001275176A1 (en) Cardiac disease treatment and device
AU2003243551A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
AU2001281369A1 (en) Cardiac disease treatment and device
AU2002227300A1 (en) Reducing cellular damage in the human body
IL187512A0 (en) Use of (s,s)-reboxetine in the treatment of pain conditions and incontinence
GB0109414D0 (en) Well treatment fluids and methods for the use thereof
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
AU4289100A (en) Dihydropyrimidines and their use in the treatment of hepatitis
HUP0400069A3 (en) Pharmaceutical combinations and their use in preventing and treating the thrombosis
AU1164601A (en) Therapeutic use and formulation
WO2003099841A9 (fr) Peptides et utilisation associee dans la coloration de la peau
AU5240700A (en) Naphthoquinone derivatives and their use in the treatment and control of tuberculosis
AU2837301A (en) Use of polymeric material in the treatment of hard surfaces
AU2002243363A1 (en) Use of aziridino-compounds in the treatment of immune dysfunctions
AU2003238242A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
AU2001292797A1 (en) Metal complexes for use in medical and therapeutic applications
AU2001261375A1 (en) Human caspase-12 materials and methods
GB0011052D0 (en) Medical device and use thereof